Ticker > Company >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  2.9 L   1.9 K   496

894.90
-1.80 (-0.20%)
BSE: 11 Sep 04:01 PM

Price Summary

Today's High

₹ 904

Today's Low

₹ 887.3

52 Week High

₹ 922.55

52 Week Low

₹ 422.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

48308.93 Cr.

Enterprise Value

50582.93 Cr.

No. of Shares

53.98 Cr.

P/E

94.81

P/B

10.29

Face Value

₹ 2

Div. Yield

0.13 %

Book Value (TTM)

₹  86.99

CASH

50.64 Cr.

DEBT

2324.64 Cr.

Promoter Holding

27.59 %

EPS (TTM)

₹  9.44

Sales Growth

8.41%

ROE

8.72 %

ROCE

10.44%

Profit Growth

70.04 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Laurus Labs Ltd.

Lasinone Trilawil Prolavir LR Trilavir Mini Myvajra

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.41%
3 Year3.49%
5 Year13.28%

Profit Growth

1 Year70.04%
3 Year-20.25%
5 Year7.33%

ROE%

1 Year8.72%
3 Year11.55%
5 Year20.32%

ROCE %

1 Year10.44%
3 Year13.42%
5 Year20.48%

Debt/Equity

0.5123

Price to Cash Flow

89.45

Interest Cover Ratio

3.7651

CFO/PAT (5 Yr. Avg.)

1.17159121624922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 27.59 2.69
Mar 2025 27.62 2.69
Dec 2024 27.62 2.69
Sep 2024 27.18 0.00
Jun 2024 27.18 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 23.6628477357467% in the last 5 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.17159121624922.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.46757215951611.

 Limitations

  • The company has shown a poor profit growth of -20.2546738551189% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.48806787274689% for the Past 3 years.
  • The company is trading at a high PE of 94.81.
  • The company is trading at a high EV/EBITDA of 41.3594.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1116.93 1184.85 1265.19 1650.01 1432.75
Total Expenditure 955.54 1003.02 1058.91 1255.18 1105.37
Operating Profit 161.39 181.83 206.28 394.83 327.38
Other Income 9.3 11.89 7.12 72.16 21.52
Interest 40.89 44.69 48.02 48.6 43.89
Depreciation 91 90.94 88.66 88.19 93.57
Exceptional Items 0 0 0 0 0
Profit Before Tax 38.8 58.09 76.72 330.2 211.44
Tax 10.02 15.65 19.45 78.3 53.5
Profit After Tax 28.78 42.44 57.27 251.9 157.94
Adjusted EPS (Rs) 0.53 0.79 1.06 4.67 2.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 4768.72 4707.04 5773.45 4812.39 5216.98
Total Expenditure 3258.85 3421.84 4291.69 4062.51 4272.65
Operating Profit 1509.87 1285.2 1481.76 749.88 944.33
Other Income 27.32 21.55 15.95 47.42 100.47
Interest 65.92 95.86 145.7 150.82 182.2
Depreciation 196.64 235.48 300.58 345.01 358.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 1274.63 975.41 1051.43 301.47 503.81
Tax 318.52 225.32 291.05 77.77 123.42
Net Profit 956.11 750.09 760.38 223.7 380.39
Adjusted EPS (Rs.) 17.82 13.96 14.12 4.15 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 107.32 107.47 107.73 107.79 107.85
Total Reserves 2604.92 3280.74 3949.09 4099.26 4456.1
Borrowings 382.64 549.67 565.49 490.53 414.25
Other N/C liabilities 178.68 236.55 229.33 234.11 446.51
Current liabilities 2696.26 2899.57 2844.09 3545.04 4109.3
Total Liabilities 5969.82 7074 7695.73 8476.73 9534.01
Assets
Net Block 1818.04 2186.23 2884.16 3036.31 2887.5
Capital WIP 324.17 755.03 357.06 155.51 336.24
Intangible WIP 0 0 0 0 0
Investments 318.89 361.72 384.12 634.87 740.22
Loans & Advances 91.84 69.82 132.84 292.11 591.9
Other N/C Assets 30.8 31.16 28.52 31.57 24.11
Current Assets 3386.08 3670.04 3909.03 4326.36 4954.04
Total Assets 5969.82 7074 7695.73 8476.73 9534.01
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1274.63 975.41 1051.43 301.47 503.81
Adjustment 240.43 322.36 442.51 478.32 498.63
Changes in Assets & Liabilities -594.55 -308.46 -344.26 -23.27 -327.99
Tax Paid -226.06 -166.34 -268.13 -97.98 -134.39
Operating Cash Flow 694.45 822.97 881.55 658.54 540.06
Investing Cash Flow -899.68 -836.61 -735.27 -756.74 -591.65
Financing Cash Flow 243.13 15.19 -185.19 139.41 59.32
Net Cash Flow 37.9 1.55 -38.91 41.21 7.73

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 27.18 27.18 27.62 27.62 27.59
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.49 2.49 2.65 2.65 2.65
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.02 23.02 23.02 23.02 22.99
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
satyanarayana chava - - 0.29 0.29 0.29
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 72.82 72.82 72.38 72.38 72.41
akash bhanshali 1.33 1.33 1.33 1.33 1.32
anukar projects private l... 3.24 3.24 3.24 3.24 3.24
barclays wealth trustees ... 1.21 1.14 1.14 1.14 1.61
kotak funds - india midca... 1.33 1.39 1.39 1.16 1.13
life insurance corporatio... 2.70 2.70 2.70 2.70 2.17
new world fund inc 6.50 6.50 6.50 6.50 6.49
sbi arbitrage opportuniti... - - - 1.82 1.64
smallcap world fund, inc 4.09 4.09 4.25 4.25 4.25
dsp arbitrage fund - - - 1.16 -
goldman sachs funds - gol... - - 1.18 1.18 -
vanguard total internatio... - 1.00 1.00 1.02 -
dsp equity opportunities ... - - 1.25 - -
sbi large & midcap fund - 2.53 2.11 - -
amansa holdings private l... 2.21 2.14 - - -
mirae asset elss tax save... 5.24 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation H1FY24

Company News

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Laurus Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Laurus Labs has a PE ratio of 94.8809221120434 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Laurus Labs has ROA of 4.224% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Laurus Labs has a Current ratio of 1.2056.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Laurus Labs has a ROE of 8.721%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Laurus Labs has a Debt to Equity ratio of 0.5123 which means that the company has low proportion of debt in its capital.

  • Sales growth: Laurus Labs has reported revenue growth of 8.4073% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Laurus Labs for the current financial year is 18.1010853022247%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Laurus Labs is Rs 1.2 and the yield is 0.134%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Laurus Labs is Rs 9.4392. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Laurus Labs in Ticker for free. Also, one can get the intrinsic value of Laurus Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Laurus Labs FAQs

Q1. What is Laurus Labs share price today?
Ans: The current share price of Laurus Labs is Rs 895.6.

Q2. What is the market capitalisation of Laurus Labs?
Ans: Laurus Labs has a market capitalisation of Rs 48346.71795444 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Laurus Labs?
Ans: The PE ratio of Laurus Labs is 94.8809221120434 and the P/B ratio of Laurus Labs is 10.2953297413867, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Laurus Labs share?
Ans: The 52-week high share price of Laurus Labs is Rs 922.5, and the 52-week low share price of Laurus Labs is Rs 427.05.

Q5. Does Laurus Labs pay dividends?
Ans: Currently, Laurus Labs pays dividends. Dividend yield of Laurus Labs is around 0.134%.

Q6. What are the face value and book value of Laurus Labs shares?
Ans: The face value of Laurus Labs shares is Rs 2, while the book value per share of Laurus Labs is around Rs 86.9909. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Laurus Labs?
Ans: Laurus Labs has a total debt of Rs 2324.64 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Laurus Labs?
Ans: The ROE of Laurus Labs is 8.721% and ROCE of Laurus Labs is 10.4378%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Laurus Labs a good buy for the long term?
Ans: The Laurus Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Laurus Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Laurus Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Laurus Labs’s financials?
Ans: You can review Laurus Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Laurus Labs
X